Agios Receives FDA Orphan Drug Designation for Tebapivat in Myelodysplastic Syndromes
Details : AG-946 (tebapivat) is an investigational pyruvate kinase (PK) activator, which is under clinical development fot the potential treatment for anemia in adults with lower-risk myelodysplastic syndromes.
Product Name : AG-946
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2024
Details : AG-946 is an investigational pyruvate kinase (PK) activator, which is under clinical development fot the potential treatment for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS).
Product Name : AG-946
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2023
Lead Product(s) : Tebapivat
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AG-946, is a novel small molecule that activates the enzyme pyruvate kinase which contributes to the production of energy in the RBC. By helping to increase energy, RBC functionality and survival may be improved.
Product Name : AG-946
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Tebapivat
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
